Prosztatarák: vizsgálatok itt: Egyesült Királyság
105 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- London, Sutton
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - No phaseTaking peopleA Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
- Where
- Many Locations
- Életkor
- 18 év and over
- People
- 1600 worldwide
- Run by
- Bayer
See details and how to joinNCT07344779 - 3. fázisNot yet taking people in Egyesült KirályságAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- London, Middlesbrough, Southampton, Truro
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - No phaseNot yet taking people in Egyesült KirályságProstate Cancer in UK Prisons: A Retrospective Data Analysis
- Where
- Sutton
- Életkor
- 18 év and over
- People
- 9007
- Run by
- Royal Marsden NHS Foundation Trust
See details and how to joinNCT07870707 - 3. fázisTaking peopleStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Where
- London, Oxford, Sutton, Windsor
- Életkor
- 18 év to 100 év
- People
- 940 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06855277 - 3. fázisNot yet taking people in Egyesült KirályságSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Cambridge, Glasgow, London, Manchester, Plymouth
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford, London, Manchester, Newcastle, Plymouth, Preston, Romford
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisFut, nem toborozThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Blackburn, Cardiff, London, Maidstone, Manchester, Plymouth, Torquay
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1/2. fázisNot yet taking people in Egyesült KirályságPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Where
- Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
- Életkor
- 18 év to 99 év
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07590934 - 1/2. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Cambridge, London
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - 1/2. fázisTaking peopleAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
- Where
- London, Sutton
- Életkor
- 18 év and over
- People
- 188 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00 - No phaseNot yet taking people in Egyesült KirályságIdentifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer
- Where
- London
- Életkor
- 18 év and over
- People
- 100 000
- Run by
- Imperial College London
See details and how to joinNCT07264088 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Glasgow, Scotland, London, Newcastle upon Tyne
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- London, Newcastle upon Tyne
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 1. fázisTaking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Cambridge, London, Middlesex
- Életkor
- 18 év and over
- People
- 1394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - 1/2. fázisTaking peopleHTL0039732 in Participants With Advanced Solid Tumours
- Where
- Cambridge, Cardiff, Dundee, Liverpool, London, Manchester
- Életkor
- 18 év and over
- People
- 150
- Run by
- Cancer Research UK
See details and how to joinNCT05944237 - 1. fázisTaking peopleA Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- Where
- Leicester, London, Sutton
- Életkor
- 18 év and over
- People
- 83 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07277270 · EU 2025-522274-37-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Cambridge, Dundee, London, Manchester
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - No phaseNot yet taking people in Egyesült KirályságMonitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.
- Where
- Liverpool
- Életkor
- 18 év and over
- People
- 40
- Run by
- The Clatterbridge Cancer Centre NHS Foundation Trust
See details and how to joinNCT07837063 - No phaseTaking peopleTo Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
- Where
- Coventry
- Életkor
- 18 év and over
- People
- 850 worldwide
- Run by
- XEOS Medical
See details and how to joinNCT06970275 - No phaseTaking peoplePRostate Cancer Enhanced Diagnosis by Calibration Technology
- Where
- London
- Életkor
- 18 év and over
- People
- 66
- Run by
- Gold Standard Phantoms
See details and how to joinNCT06607783 - No phaseNot yet taking people in Egyesült KirályságAdvanced Diffusion Magnetic reSonance Prostate Imaging for Reducing Extraneous Biopsies (ASPIRE) - Calibration Component (Multi-centre Scanner Calibration) and Validation Component (Multi-centre Validation)
- Where
- London
- Életkor
- 18 év and over
- People
- 660
- Run by
- University College, London
See details and how to joinNCT07808528 - 1/2. fázisTaking peopleInvestigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
- Where
- Belfast, Cambridge, Sutton
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- Institute of Cancer Research, United Kingdom
See details and how to joinNCT07002320 - 2. fázisTaking peopleA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Where
- London
- Életkor
- 18 év and over
- People
- 218 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00 - 1/2. fázisTaking peopleA Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Where
- Cambridge, Manchester
- Életkor
- 18 év and over
- People
- 52 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00